Brief Introduction on High-value Drug Insurance Access Mechanism in Australia and Its Enlightenment on Orphan Drug Medical Insurance in China
10.6039/j.issn.1001-0408.2017.04.08
- VernacularTitle:澳大利亚高值药物医保准入机制简介及对我国罕用药医保准入的启示
- Author:
Fang REN
;
Jianzhou YAN
;
Rong SHAO
- Keywords:
Australia;
High-value drug;
Insurance access mechanism;
Orphan drug;
Enlightenment
- From:
China Pharmacy
2017;28(4):462-464,465
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To introduce high-value drug insurance access mechanism in Australia,and to provide suggestion for improving orphan drug medical insurance access in China. METHODS:By literature study and policy analysis,access principle, risk-sharing mechanism and restricted use principle of high-value drug insurance access in Australia were summarized and analyzed, so as to evaluate the effects of high-value drug insurance access mechanism. RESULTS & CONCLUSIONS:The inclusion of high-value drug in Australian National Formulary considers not only the cost-effectiveness ratio,but also the drug’s clinical effica-cy,irreplaceability and the social principles;risk-sharing mechanism and restricted use principle achieve a good balance between the accessibility of patient’s medication and the sustainability of health insurance fund;remarkable results are achieved in guarantee-ing patient’s medication and strengthening basic medical insurance. It is recommended to perfect orphan drugs medical insurance ac-cess standard,introduce risk-sharing mechanism and standardize the use of orphan drugs and reimbursement in China.
